It is a slow news period for CytoDyn right now so I thought I'd give you something else to ponder[color=var(--text)]....[/color]
I know it would be In the distant future but Ohm included diabetes on his list of potential targets for Leronlimab. (An estimated 40.1 million people (or about 12% of the U.S. population) have diagnosed or undiagnosed diabetes. Out of this total, 29.1 million are diagnosed, while approximately 11 million remain undiagnosed.)
Here's the AI Overview:
Leronlimab blocks the CCR5 receptor to prevent chronic inflammation and insulin resistance. In conditions like obesity and Type 2 diabetes, immune cells cause adipose tissue inflammation. By inhibiting this pathway, leronlimab reduces pro-inflammatory cytokines (like IL-6) and restores immune cell function to potentially protect metabolic health.
While leronlimab is primarily developed for HIV and oncology, its anti-inflammatory actions are relevant to diabetes pathology.
Key Mechanisms in Diabetes
Reducing Insulin Resistance: In metabolic diseases, CCR5 receptors on immune cells promote inflammation in adipose (fat) tissue, which directly drives insulin resistance. By blocking CCR5, leronlimab mimics CCR5 deficiency, which limits this inflammatory response and helps restore insulin sensitivity.
Lowering Inflammation: The interaction of the CCR5 receptor and its ligands (like CCL5) triggers the release of pro-inflammatory cytokines. Leronlimab inhibits this signaling pathway, resulting in decreased systemic inflammation and a reduction in proteins like IL-6, both of which are central to diabetes complications.
Regulating Immune Balance: Dysregulation of the CCR5/CCL5 axis contributes to the progression of Type 1 diabetes by altering regulatory T cell (Treg) function. Blocking CCR5 may help restore immune tolerance and stop the autoimmune destruction of insulin-producing pancreatic cells.
The possibilities seem endless!
I know it would be In the distant future but Ohm included diabetes on his list of potential targets for Leronlimab. (An estimated 40.1 million people (or about 12% of the U.S. population) have diagnosed or undiagnosed diabetes. Out of this total, 29.1 million are diagnosed, while approximately 11 million remain undiagnosed.)
Here's the AI Overview:
Leronlimab blocks the CCR5 receptor to prevent chronic inflammation and insulin resistance. In conditions like obesity and Type 2 diabetes, immune cells cause adipose tissue inflammation. By inhibiting this pathway, leronlimab reduces pro-inflammatory cytokines (like IL-6) and restores immune cell function to potentially protect metabolic health.
While leronlimab is primarily developed for HIV and oncology, its anti-inflammatory actions are relevant to diabetes pathology.
Key Mechanisms in Diabetes
Reducing Insulin Resistance: In metabolic diseases, CCR5 receptors on immune cells promote inflammation in adipose (fat) tissue, which directly drives insulin resistance. By blocking CCR5, leronlimab mimics CCR5 deficiency, which limits this inflammatory response and helps restore insulin sensitivity.
Lowering Inflammation: The interaction of the CCR5 receptor and its ligands (like CCL5) triggers the release of pro-inflammatory cytokines. Leronlimab inhibits this signaling pathway, resulting in decreased systemic inflammation and a reduction in proteins like IL-6, both of which are central to diabetes complications.
Regulating Immune Balance: Dysregulation of the CCR5/CCL5 axis contributes to the progression of Type 1 diabetes by altering regulatory T cell (Treg) function. Blocking CCR5 may help restore immune tolerance and stop the autoimmune destruction of insulin-producing pancreatic cells.
The possibilities seem endless!
15
